10-K/A: Kairos Pharma Amends Annual Report to Detail Executive Compensation and Corporate Governance

Kairos Pharma, Ltd. filed an amendment to its 2024 Annual Report to include detailed information on executive compensation, corporate governance, and related party transactions, ensuring SEC compliance.

Summary

• The filing is Amendment No. 2 to Kairos Pharma, Ltd.'s Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
• Its primary purpose is to add information required by Items 10 through 14 of Part III, which were previously omitted from the Original Form 10-K filed on April 15, 2025.
• The omitted information, pertaining to directors, executive officers, corporate governance, executive compensation, security ownership, and related party transactions, had been filed in the company's Definitive Proxy Statement on Schedule 14A.
• This amendment ensures the Annual Report on Form 10-K is deemed complete by the SEC.
• No financial statements are included in this amendment, and it does not modify or update any previously reported financial results.
• The company's common stock is traded on the NYSE American under the symbol KAPA.
• As of July 28, 2025, Kairos Pharma had 20,457,480 shares of Common Stock outstanding.

Sentiment

Score: 7

Explanation: The filing is primarily a compliance update, demonstrating the company's efforts to formalize its corporate governance and compensation structures post-IPO. The establishment of independent board committees, a clawback policy, and an insider trading policy are positive steps for transparency and accountability. The noted late Section 16(a) filings are minor administrative issues. Overall, the content reflects expected maturation for a newly public company, contributing positively to investor confidence in governance, despite not containing new operational or financial performance data.

Positives

• The company has established a board of directors with a majority of independent members (three out of four), aligning with NYSE American listing standards.
• Key board committees, including Audit, Compensation, and Nominating and Corporate Governance, have been established and are composed entirely of independent directors.
• An audit committee financial expert, Dr. Michael Keyoung, has been identified, enhancing financial oversight.
• A comprehensive compensation philosophy is in place, designed to attract, motivate, and retain talent while aligning management interests with stockholder value.
• The company adopted a clawback policy on March 1, 2024, allowing for the recovery of erroneously awarded compensation due to financial restatements from misconduct.
• An insider trading policy has been adopted, prohibiting trading on material non-public information and restricting certain speculative transactions.
• The company has a policy requiring board or audit committee review and approval for significant related party transactions, promoting transparency and fairness.

Negatives

• Two Section 16(a) reports were filed late: Doug Samuelson's Form 4 (transaction on November 22, 2024, filed on November 25, 2024) and Rahul Singhvi's Form 3 (transaction on December 10, 2024, filed on April 30, 2025).

Risks

• The filing discusses the board's role in risk oversight, noting that risks are considered in business decisions and as part of strategy, and that management is charged with managing risk. However, no specific business or operational risks are detailed within this amendment.

Future Outlook

The filing primarily focuses on historical corporate governance and compensation disclosures for compliance purposes. It does not provide specific forward-looking statements regarding business performance, financial guidance, or strategic initiatives beyond the general intent to align compensation with long-term stockholder value and ongoing compliance with SEC and NYSE American rules.

Management Comments

• Our compensation program is designed to attract, motivate, and retain highly talented executives, and to provide competitive compensation opportunities that align management's interests with the shortand long-term interests of our stockholders.
• Our incentive compensation plans are designed with the objectives of motivating the desired performance and maximizing stockholder value.
• We believe that our compensation program, supported by our underlying compensation philosophy, serves to motivate management to execute on the strategic and operational plans that will deliver increases in stockholder value over the long-term.
• We value input from our stockholders on our executive compensation programs and seek an annual non-binding advisory vote from stockholders to approve our executive compensation.

Industry Context

Kairos Pharma, a biotechnology company focused on cancer therapeutics, is navigating the post-IPO landscape by formalizing its corporate governance and executive compensation structures. This filing reflects standard compliance efforts for a newly public company, establishing transparent frameworks for board oversight, executive incentives, and related party transactions. The detailed disclosures on executive and director compensation, including equity awards, are typical for biotech firms aiming to attract and retain specialized talent in a competitive industry.

Comparison to Industry Standards

• The company's board composition, with three out of four directors being independent, aligns with the majority independence requirements of NYSE American listing standards, a common benchmark for public companies.
• The establishment of dedicated Audit, Compensation, and Nominating and Corporate Governance committees, each composed of independent directors, is a standard best practice for corporate governance in publicly traded companies, including those in the biotechnology sector.
• The adoption of a clawback policy for erroneously awarded compensation and a comprehensive insider trading policy demonstrates adherence to post-Sarbanes-Oxley governance principles and aims to mitigate financial and reputational risks, consistent with industry best practices.
• The executive compensation structure, which includes a mix of base salary and long-term equity incentives (Restricted Stock Units), is a common approach in the biotechnology industry to align management's interests with long-term shareholder value, similar to companies like Celgene (now Bristol Myers Squibb) or Xencor Inc., where some of Kairos's executives have prior experience.
• The policy requiring board or audit committee review for significant related party transactions is a standard governance control, comparable to practices seen across public companies to ensure arm's-length dealings and protect shareholder interests.

Management Changes

Corporate Governance

Legal Proceedings

• No directors or executive officers have been involved in certain legal proceedings (e.g., criminal convictions, bankruptcies, injunctions, securities law violations) during the past ten years, to the best of the company's knowledge.

Related Party Transactions

• In August 2024, the company borrowed $40,000 from one of its officers. The loan accrues interest at 7.5% per annum, is unsecured, and is due in August 2025.
• In April and May 2024, the company borrowed $100,000 from three of its officers. These loans accrue interest at 7.5% per annum, are unsecured, and are due in April 2025. The officers have since agreed to convert these outstanding loans and principal into shares of common stock at the IPO per share purchase price following the IPO.
• During 2021, stockholders of the company and a company whose principal stockholder is also a stockholder of Kairos Pharma advanced $10,000 to the company. These advances accrue no interest, are unsecured, and are due on demand. As of December 31, 2022, 2023, and June 30, 2024, $4,000 remained outstanding.
• The company has a policy requiring any transaction with a related person exceeding $120,000 (or 1% of average total assets) to be presented to the board of directors or audit committee for review and approval, ensuring terms are no less favorable than those with unaffiliated third parties.

Stakeholder Impact

• Shareholders: Enhanced transparency and corporate governance structures post-IPO, including detailed executive compensation and related party disclosures. The adoption of a clawback policy and insider trading policy aims to protect shareholder interests. The conversion of officer loans into common stock could dilute existing shareholders but also demonstrates management's commitment.
• Employees: Executive compensation structure aims to attract and retain highly talented executives, potentially benefiting overall company performance and stability. The 2023 Equity Incentive Plan provides opportunities for equity-based awards.
• Management: Clear compensation policies, including base salary and equity incentives, and defined severance terms. Subject to clawback policy for misconduct-related restatements.
• Creditors: Loans from officers and stockholders indicate internal financing, with some loans carrying interest, while others are interest-free and due on demand.

Next Steps

• The board seeks an annual non-binding advisory vote from stockholders to approve executive compensation.
• The Compensation Committee will review and consider the compensation philosophy at least annually.
• The board of directors may establish other committees as deemed necessary or appropriate from time to time.
• The company intends to disclose any future amendments or waivers to its Code of Business Conduct and Ethics on its website.

Key Dates

Recommendation

This filing is an amendment primarily focused on corporate governance and executive compensation disclosures, which are standard compliance requirements for a newly public company. It does not contain new financial performance data or strategic updates that would warrant a 'buy' or 'sell' recommendation. The establishment of robust governance structures and policies is a positive for long-term stability, but the late Section 16(a) filings indicate minor administrative issues. Given the lack of new operational or financial news, a 'hold' recommendation is appropriate as investors await further business developments.

Keywords

Kairos Pharma, KAPA, SEC Filing, 10-K/A, Annual Report Amendment, Corporate Governance, Executive Compensation, Board of Directors, Biotechnology, Pharmaceuticals, Risk Management, Related Party Transactions, SEC Compliance, IPO